Synergistic Hypotensive Effect of Vasoactive Intestinal Polypeptide and α-Blockade With Phentolamine Evidence for Vasoactive Intestinal Peptide α-Adrenoceptor Coupling in the Cardiovascular System of Newborn Dogs

Vasoactive intestinal polypeptide (VIP) is a neuropeptide with potent circulatory effects in the adult animal and human. Little is known about its effects or mechanism of action in the immature animal. These series of experiments evaluated the effects and possible mechanism of action of VIP on the d...

Full description

Saved in:
Bibliographic Details
Published in:Circulation research 1990-10, Vol.67 (4), p.986-992
Main Authors: Mas, Madeleen S, Adams, David J, Gelband, Henry
Format: Article
Language:English
Subjects:
Animals
Animals, Newborn - physiology
Biological and medical sciences
Blood Pressure - drug effects
Cardiovascular Physiological Phenomena
Cardiovascular system
Cardiovascular System - drug effects
Cardiovascular System - growth & development
Denervation
Dogs
Drug Synergism
Female
Heart Rate - drug effects
Male
Medical sciences
Parasympathetic Nervous System - physiology
Pharmacology. Drug treatments
Phentolamine - pharmacology
Propranolol - pharmacology
Receptors, Adrenergic, alpha - physiology
Vagotomy
Vasoactive Intestinal Peptide - pharmacology
Vasoactive Intestinal Peptide - physiology
Vasodilator agents. Cerebral vasodilators
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vasoactive intestinal polypeptide (VIP) is a neuropeptide with potent circulatory effects in the adult animal and human. Little is known about its effects or mechanism of action in the immature animal. These series of experiments evaluated the effects and possible mechanism of action of VIP on the developing canine cardiovascular system. In all three series, measurements of mean heart rate and blood pressure were taken in the control state, after parasympathetic denervation with bilateral cervical vagotomies, and after autonomic blockade with propranolol (1 mg/kg) and phentolamine (0.5 mg i.v.). In series 1, we characterized the role of α-adrenergic receptors in early newborn puppies by investigating the hemodynamic effects of phentolamine alone in five early newborn puppies. In series 2, the hemodynamic effects of intravenous VIP infusion (0.2 μg/kg/min) were recorded and compared in six early newborn puppies and in 10 late newborn puppies. In series 3, the hemodynamic effects of phentolamine in the presence of VIP receptor binding inhibitor were studied. In early newborn puppies, VIP had essentially no effect on heart rate or blood pressure until phentolamine was given; then, blood pressure decreased by 17% (p
ISSN:0009-7330
1524-4571
DOI:10.1161/01.RES.67.4.986